• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ: REGN )

    1,057.74 +13.35 (+1.28%)
    Streaming Delayed Price Updated: 3:33 PM EDT, Jun 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 533,473
    Open 1,047.71
    Bid (Size) 1,056.24 (5)
    Ask (Size) 1,057.82 (4)
    Prev. Close 1,044.39
    Today's Range 1,041.25 - 1,057.82
    52wk Range 684.80 - 1,052.34
    Shares Outstanding 91,779,465
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
    Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
    Via Benzinga
    Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024
    Investors looking for companies with high growth potential should consider investing in these three strong buy Cathie Wood stocks. 
    Via InvestorPlace

    Performance

    YTD
    +16.88%
    +16.88%
    1 Month
    +6.42%
    +6.42%
    3 Month
    +9.27%
    +9.27%
    6 Month
    +25.64%
    +25.64%
    1 Year
    +35.82%
    +35.82%

    More News

    Read More
    $100 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
    Via Benzinga
    Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Peering Into Regeneron Pharmaceuticals's Recent Short Interest
    Via Benzinga
    Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
    Via Benzinga
    Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals
    Via Benzinga
    Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
    Via Benzinga
    Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
    Via Investor's Business Daily
    Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
    Via Investor's Business Daily
    Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
    Via Benzinga
    2 Biotech Stocks to Buy in May
    Via The Motley Fool
    (REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
    Via Benzinga
    Stock Split Watch: 3 Growth Stocks That Could Be Next
    Via The Motley Fool
    What's Going On With FibroGen Stock Tuesday?
    Via Benzinga
    Exposures Product Safety
    FibroGen Stock Is Surging After The Bell: What's Going On?
    Via Benzinga
    Exposures Product Safety
    Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
    Via Benzinga
    FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
    Via Benzinga
    Exposures Product Safety
    Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    What's Going On With Biohaven Stock Wednesday?
    Via Benzinga
    After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
    Via Benzinga
    Topics Data Breach
    Exposures Information Security
    Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years
    Via The Motley Fool
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.